ClinicalTrials.gg
CompletedNCT04476043Updated Aug 12, 2025Results posted

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

A Phase 2 interventional study of INCB054707 and Placebo in Hidradenitis Suppurativa and Acne Inversa, sponsored by Incyte Corporation. Completed at 40 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
209
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.

Enrollment
7th of 12
209 · median 391
Started
2020
the only one that year
Phase 2
5 of 12
1 open now
Registered
3rd of 12
by date

Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 5 in phase 2, and was the 3rd registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hidradenitis Suppurativa by Incyte Corporation, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).

03

Conditions studied

  • Hidradenitis Suppurativa
  • Acne Inversa
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • HS disease duration of at least 3 months before screening.
  • Willingness to avoid pregnancy or fathering children.
  • Active HS in at least 2 distinct anatomical areas.
  • Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period

Exclusion criteria

Exclusion Criteria:

  • Draining fistula count of > 20 at screening or baseline.
  • Women who are pregnant (or who are considering pregnancy) or lactating.
  • Medical history including thrombocytopenia, coagulopathy or dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
  • History of failure to treatment of inflammatory diseases with JAK inhibitors.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
  • Participants known to be infected with , , or .
  • Laboratory values outside of the protocol-defined ranges.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
209 participants (actual)

Study arms

  • Experimental
    INCB054707 15 mg

    Participants will receive INCB054707 15 milligrams (mg) for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.

    Drug: INCB054707

  • Experimental
    INCB054707 45 mg

    Participants will receive INCB054707 45 mg for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.

    Drug: INCB054707

  • Experimental
    INCB054707 75 mg

    Participants will receive INCB054707 75 mg for 52 weeks in the Placebo-controlled Treatment Period (16 weeks) plus the Open-label Extension Period (36 weeks). Participants will have the option to continue open-label treatment for an additional 48 weeks.

    Drug: INCB054707

  • Placebo comparator
    Placebo followed by INCB054707 75 mg

    Participants will receive placebo for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.

    Drug: Placebo

Interventions

  • Oral; Tablet

    Also known as: Povorcitinib

  • DrugPlacebo

    Oral; Tablet

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The mixed model repeated measure (MMRM) included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.

    Time frame: Baseline; Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16

    HiSCR, the key secondary endpoint, was defined as at least a 50% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.

    Time frame: Baseline; Week 16

  2. Percentage of Participants Who Achieved a HiSCR at Weeks 2 Through 12

    HiSCR was defined as at least a 50% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.

    Time frame: Baseline; Weeks 2, 4, 6, 8, and 12

  3. Percentage of Participants Who Achieved HiSCR75 From Weeks 2 to 16

    HiSCR75 was defined as at least a 75% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.

    Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16

  4. Mean Change From Baseline in the Severity of the Disease, as Assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4) Score, From Weeks 2 to 16

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The IHS4 is a composite, dynamic score and validated tool used to determine Hidradenitis Suppurativa severity. It employs a weighted scale using the number of inflammatory nodules, the number of abscesses, and the number of draining tunnels (fistulas or sinuses), with respective weight factors of 1, 2, and 4. Scores: mild=0-3; moderate=4-10; severe ≥11. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.

    Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16

  5. Percentage of Participants Who Achieved AN50, AN75, AN90, and AN100 From Weeks 2 to 16

    AN50, AN75, AN90, and AN100 were defined as at least a 50%, 75%, 90%, and 100% decrease, respectively, from Baseline in AN count.

    Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16

  6. Mean Change From Baseline in AN Count at Weeks 2 to 12

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.

    Time frame: Baseline; Weeks 2, 4, 6, 8, and 12

  7. Percentage of Participants With a Total AN Count of 0 to 2 From Weeks 2 to 16

    Total AN count was assessed throughout the study.

    Time frame: Weeks 2, 4, 6, 8, 12, and 16

  8. Mean Change From Baseline in Draining Fistula Count From Weeks 2 to 16

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16

  9. Mean Change From Baseline in Abscess, Inflammatory Nodule (IN), and Draining Fistula (DF) (ANF) Count From Weeks 2 to 16

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.

    Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16

  10. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.

    Time frame: up to Week 16

07

Results

Posted Jan 26, 2023

Participant flow

A total of 209 participants were enrolled at 36 study centers: 26 in North America and 10 in Europe. Data are reported through the cut-off date of 15 December 2021.

Participant flow — Overall Study
MilestonePlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Started52525253
Completed48474551
Not completed4572
Withdrew: Withdrawal by subject1341
Withdrew: Lost to follow-up1121
Withdrew: Adverse event2010
Withdrew: Protocol violation0100

Outcome measures

PrimaryMean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The mixed model repeated measure (MMRM) included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.

Time frame:
Baseline; Week 16
Reported as:
Least squares mean · abscesses and inflammatory nodules
Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16
abscesses and inflammatory nodulesPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16-2.5 ± 0.88-5.2 ± 0.86-6.9 ± 0.88-6.3 ± 0.85
Statistical analysis
  • Placebo vs INCB054707 15 mg · MMRM · p = 0.0277 · Least squares mean (lsm) difference: -2.7 · 95% CI -5.2 to -0.3
  • Placebo vs INCB054707 45 mg · MMRM · p = 0.0006 · Lsm difference: -4.4 · 95% CI -6.8 to -1.9
  • Placebo vs INCB054707 75 mg · MMRM · p = 0.0021 · Lsm difference: -3.8 · 95% CI -6.2 to -1.4
SecondaryPercentage of Participants Who Achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16

HiSCR, the key secondary endpoint, was defined as at least a 50% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.

Time frame:
Baseline; Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
percentage of participantsPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Percentage of Participants Who Achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 1628.8 (17.1 to 43.1)48.1 (34.0 to 62.4)44.2 (30.5 to 58.7)45.3 (31.6 to 59.6)
Statistical analysis
  • Placebo vs INCB054707 15 mg · Wald test · p = 0.0445 · Odds ratio (or): 2.3 · 95% CI 1.0 to 5.3Logistic regression model with treatment group and stratification factors (disease severity and geographical region).
  • Placebo vs INCB054707 15 mg · Difference in response rate: 19.2Standard error of difference between response rates was from normal approximation.
  • Placebo vs INCB054707 45 mg · Wald test · p = 0.0998 · Odds ratio (or): 2.0 · 95% CI 0.9 to 4.6Logistic regression model with treatment group and stratification factors (disease severity and geographical region).
  • Placebo vs INCB054707 45 mg · Difference in response rate: 15.4Standard error of difference between response rates was from normal approximation.
  • Placebo vs INCB054707 75 mg · Wald test · p = 0.0829 · Odds ratio (or): 2.1 · 95% CI 0.9 to 4.7Logistic regression model with treatment group and stratification factors (disease severity and geographical region).
  • Placebo vs INCB054707 75 mg · Difference in response rate: 16.4Standard error of difference between response rates was from normal approximation.
SecondaryPercentage of Participants Who Achieved a HiSCR at Weeks 2 Through 12

HiSCR was defined as at least a 50% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.

Time frame:
Baseline; Weeks 2, 4, 6, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a HiSCR at Weeks 2 Through 12
percentage of participantsPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Week 215.4 (6.9 to 28.1)25.0 (14.0 to 38.9)34.6 (22.0 to 49.1)34.0 (21.5 to 48.3)
Week 425.0 (14.0 to 38.9)36.5 (23.6 to 51.0)44.2 (30.5 to 58.7)49.1 (35.1 to 63.2)
Week 617.3 (8.2 to 30.3)32.7 (20.3 to 47.1)48.1 (34.0 to 62.4)52.8 (38.6 to 66.7)
Week 828.8 (17.1 to 43.1)36.5 (23.6 to 51.0)44.2 (30.5 to 58.7)52.8 (38.6 to 66.7)
Week 1230.8 (18.7 to 45.1)42.3 (28.7 to 56.8)48.1 (34.0 to 62.4)58.5 (44.1 to 71.9)
SecondaryPercentage of Participants Who Achieved HiSCR75 From Weeks 2 to 16

HiSCR75 was defined as at least a 75% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.

Time frame:
Baseline; Weeks 2, 4, 6, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR75 From Weeks 2 to 16
percentage of participantsPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Week 21.9 (0.0 to 10.3)9.6 (3.2 to 21.0)13.5 (5.6 to 25.8)18.9 (9.4 to 32.0)
Week 47.7 (2.1 to 18.5)15.4 (6.9 to 28.1)21.2 (11.1 to 34.7)15.1 (6.7 to 27.6)
Week 69.6 (3.2 to 21.0)17.3 (8.2 to 30.3)28.8 (17.1 to 43.1)24.5 (13.8 to 38.3)
Week 819.2 (9.6 to 32.5)23.1 (12.5 to 36.8)30.8 (18.7 to 45.1)35.8 (23.1 to 50.2)
Week 1219.2 (9.6 to 32.5)26.9 (15.6 to 41.0)32.7 (20.3 to 47.1)39.6 (26.5 to 54.0)
Week 1617.3 (8.2 to 30.3)30.8 (18.7 to 45.1)28.8 (17.1 to 43.1)30.2 (18.3 to 44.3)
SecondaryMean Change From Baseline in the Severity of the Disease, as Assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4) Score, From Weeks 2 to 16

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The IHS4 is a composite, dynamic score and validated tool used to determine Hidradenitis Suppurativa severity. It employs a weighted scale using the number of inflammatory nodules, the number of abscesses, and the number of draining tunnels (fistulas or sinuses), with respective weight factors of 1, 2, and 4. Scores: mild=0-3; moderate=4-10; severe ≥11. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.

Time frame:
Baseline; Weeks 2, 4, 6, 8, 12, and 16
Reported as:
Least squares mean · scores on a scale
Mean Change From Baseline in the Severity of the Disease, as Assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4) Score, From Weeks 2 to 16
scores on a scalePlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Week 2-2.4 ± 1.17-3.8 ± 1.13-6.7 ± 1.16-6.1 ± 1.12
Week 4-2.1 ± 1.52-3.9 ± 1.49-9.3 ± 1.51-9.3 ± 1.47
Week 6-3.1 ± 1.77-4.7 ± 1.73-10.7 ± 1.75-10.6 ± 1.71
Week 8-3.0 ± 1.85-4.0 ± 1.79-11.8 ± 1.83-10.7 ± 1.78
Week 12-3.1 ± 1.80-5.5 ± 1.76-11.8 ± 1.79-11.9 ± 1.73
Week 16-3.1 ± 1.96-5.6 ± 1.92-11.0 ± 1.96-12.1 ± 1.90
SecondaryPercentage of Participants Who Achieved AN50, AN75, AN90, and AN100 From Weeks 2 to 16

AN50, AN75, AN90, and AN100 were defined as at least a 50%, 75%, 90%, and 100% decrease, respectively, from Baseline in AN count.

Time frame:
Baseline; Weeks 2, 4, 6, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved AN50, AN75, AN90, and AN100 From Weeks 2 to 16
percentage of participantsPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
AN50, Week 215.4 (6.9 to 28.1)25.0 (14.0 to 38.9)34.6 (22.0 to 49.1)39.6 (26.5 to 54.0)
AN50, Week 430.8 (18.7 to 45.1)44.2 (30.5 to 58.7)46.2 (32.2 to 60.5)58.5 (44.1 to 71.9)
AN50, Week 632.7 (20.3 to 47.1)46.2 (32.2 to 60.5)51.9 (37.6 to 66.0)56.6 (42.3 to 70.2)
AN50, Week 836.5 (23.6 to 51.0)55.8 (41.3 to 69.5)53.8 (39.5 to 67.8)54.7 (40.4 to 68.4)
AN50, Week 1244.2 (30.5 to 58.7)51.9 (37.6 to 66.0)55.8 (41.3 to 69.5)62.3 (47.9 to 75.2)
AN50, Week 1636.5 (23.6 to 51.0)55.8 (41.3 to 69.5)57.7 (43.2 to 71.3)52.8 (38.6 to 66.7)
AN75, Week 21.9 (0.0 to 10.3)9.6 (3.2 to 21.0)13.5 (5.6 to 25.8)20.8 (10.8 to 34.1)
AN75, Week 47.7 (2.1 to 18.5)15.4 (6.9 to 28.1)23.1 (12.5 to 36.8)18.9 (9.4 to 32.0)
AN75, Week 613.5 (5.6 to 25.8)25.0 (14.0 to 38.9)32.7 (20.3 to 47.1)26.4 (15.3 to 40.3)
AN75, Week 821.2 (11.1 to 34.7)28.8 (17.1 to 43.1)32.7 (20.3 to 47.1)37.7 (24.8 to 52.1)
AN75, Week 1223.1 (12.5 to 36.8)32.7 (20.3 to 47.1)36.5 (23.6 to 51.0)39.6 (26.5 to 54.0)
AN75, Week 1617.3 (8.2 to 30.3)36.5 (23.6 to 51.0)36.5 (23.6 to 51.0)34.0 (21.5 to 48.3)
AN90, Week 20.0 (0.0 to 6.8)3.8 (0.5 to 13.2)1.9 (0.0 to 10.3)11.3 (4.3 to 23.0)
AN90, Week 40.0 (0.0 to 6.8)5.8 (1.2 to 15.9)7.7 (2.1 to 18.5)5.7 (1.2 to 15.7)
AN90, Week 65.8 (1.2 to 15.9)5.8 (1.2 to 15.9)11.5 (4.4 to 23.4)9.4 (3.1 to 20.7)
AN90, Week 85.8 (1.2 to 15.9)15.4 (6.9 to 28.1)19.2 (9.6 to 32.5)18.9 (9.4 to 32.0)
AN90, Week 125.8 (1.2 to 15.9)17.3 (8.2 to 30.3)13.5 (5.6 to 25.8)20.8 (10.8 to 34.1)
AN90, Week 163.8 (0.5 to 13.2)17.3 (8.2 to 30.3)19.2 (9.6 to 32.5)18.9 (9.4 to 32.0)
AN100, Week 20.0 (0.0 to 6.8)3.8 (0.5 to 13.2)1.9 (0.0 to 10.3)7.5 (2.1 to 18.2)
AN100, Week 40.0 (0.0 to 6.8)3.8 (0.5 to 13.2)5.8 (1.2 to 15.9)5.7 (1.2 to 15.7)
AN100, Week 60.0 (0.0 to 6.8)3.8 (0.5 to 13.2)7.7 (2.1 to 18.5)9.4 (3.1 to 20.7)
AN100, Week 83.8 (0.5 to 13.2)13.5 (5.6 to 25.8)11.5 (4.4 to 23.4)17.0 (8.1 to 29.8)
AN100, Week 123.8 (0.5 to 13.2)13.5 (5.6 to 25.8)11.5 (4.4 to 23.4)18.9 (9.4 to 32.0)
AN100, Week 163.8 (0.5 to 13.2)15.4 (6.9 to 28.1)11.5 (4.4 to 23.4)17.0 (8.1 to 29.8)
SecondaryMean Change From Baseline in AN Count at Weeks 2 to 12

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.

Time frame:
Baseline; Weeks 2, 4, 6, 8, and 12
Reported as:
Least squares mean · abscesses and inflammatory nodules
Mean Change From Baseline in AN Count at Weeks 2 to 12
abscesses and inflammatory nodulesPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Week 2-1.7 ± 0.69-2.7 ± 0.66-3.4 ± 0.69-4.0 ± 0.66
Week 4-3.0 ± 0.71-3.6 ± 0.70-4.8 ± 0.71-5.3 ± 0.69
Week 6-2.7 ± 0.77-4.8 ± 0.76-5.3 ± 0.77-6.2 ± 0.75
Week 8-2.7 ± 0.82-4.7 ± 0.79-6.4 ± 0.82-5.7 ± 0.79
Week 12-2.8 ± 0.84-5.0 ± 0.82-6.7 ± 0.84-6.5 ± 0.81
SecondaryPercentage of Participants With a Total AN Count of 0 to 2 From Weeks 2 to 16

Total AN count was assessed throughout the study.

Time frame:
Weeks 2, 4, 6, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Total AN Count of 0 to 2 From Weeks 2 to 16
percentage of participantsPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Week 24.39.816.723.1
Week 414.320.020.023.1
Week 613.319.131.338.8
Week 828.930.038.341.2
Week 1228.933.346.738.8
Week 1625.644.451.237.0
SecondaryMean Change From Baseline in Draining Fistula Count From Weeks 2 to 16

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 2, 4, 6, 8, 12, and 16
Reported as:
Mean · draining fistulas
Mean Change From Baseline in Draining Fistula Count From Weeks 2 to 16
draining fistulasPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Baseline2.4 ± 3.972.3 ± 4.442.2 ± 4.041.6 ± 2.85
Change from Baseline at Week 2-0.2 ± 1.23-0.2 ± 1.01-0.6 ± 1.62-0.2 ± 1.30
Change from Baseline at Week 40.0 ± 1.800.0 ± 1.11-0.8 ± 2.59-0.6 ± 2.44
Change from Baseline at Week 6-0.2 ± 2.140.1 ± 1.85-1.0 ± 2.95-0.8 ± 2.62
Change from Baseline at Week 8-0.2 ± 2.460.2 ± 2.10-1.1 ± 2.82-0.8 ± 2.70
Change from Baseline at Week 12-0.3 ± 2.170.0 ± 2.71-1.0 ± 2.87-1.0 ± 2.61
Change from Baseline at Week 16-0.3 ± 2.050.1 ± 3.25-0.8 ± 3.20-1.1 ± 2.57
SecondaryMean Change From Baseline in Abscess, Inflammatory Nodule (IN), and Draining Fistula (DF) (ANF) Count From Weeks 2 to 16

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.

Time frame:
Baseline; Weeks 2, 4, 6, 8, 12, and 16
Reported as:
Least squares mean · abscesses, INs, and DFs
Mean Change From Baseline in Abscess, Inflammatory Nodule (IN), and Draining Fistula (DF) (ANF) Count From Weeks 2 to 16
abscesses, INs, and DFsPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Week 2-1.8 ± 0.74-2.9 ± 0.72-4.0 ± 0.74-4.4 ± 0.71
Week 4-2.7 ± 0.83-3.5 ± 0.82-5.7 ± 0.82-6.2 ± 0.80
Week 6-2.6 ± 0.92-4.7 ± 0.90-6.4 ± 0.92-7.1 ± 0.89
Week 8-2.6 ± 0.96-4.4 ± 0.93-7.5 ± 0.96-6.8 ± 0.92
Week 12-2.7 ± 0.99-5.0 ± 0.97-7.7 ± 0.98-7.6 ± 0.95
Week 16-2.4 ± 1.06-5.1 ± 1.03-7.7 ± 1.05-7.6 ± 1.02
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Number of Participants With Treatment-emergent Adverse Events (TEAEs)34313032

Adverse events

Collected over up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/52 (0%)3/52 (5.8%)15/52 (28.8%)
INCB054707 15 mg0/52 (0%)2/52 (3.8%)20/52 (38.5%)
INCB054707 45 mg0/50 (0%)1/50 (2%)17/50 (34%)
INCB054707 75 mg0/53 (0%)0/53 (0%)19/53 (35.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/520/521/500/53
Abscess limbInfections and infestations1/520/520/500/53
Atrial fibrillationCardiac disorders1/520/520/500/53
Bacterial infectionInfections and infestations1/520/520/500/53
CholecystitisHepatobiliary disorders1/520/520/500/53
FallInjury, poisoning and procedural complications0/521/520/500/53
PneumoniaInfections and infestations0/521/520/500/53
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/521/520/500/53
Rib fractureInjury, poisoning and procedural complications0/521/520/500/53
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mg
FatigueGeneral disorders4/525/526/506/53
HeadacheNervous system disorders5/524/523/504/53
NauseaGastrointestinal disorders5/523/522/503/53
ConstipationGastrointestinal disorders2/524/520/501/53
Upper respiratory tract infectionInfections and infestations2/520/521/504/53
AcneSkin and subcutaneous tissue disorders0/521/523/503/53
NasopharyngitisInfections and infestations0/523/523/500/53
Back painMusculoskeletal and connective tissue disorders1/523/521/500/53
DiarrhoeaGastrointestinal disorders1/523/522/503/53
VomitingGastrointestinal disorders0/523/522/501/53

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mgTotal
Mean35.2 ± 9.9638.2 ± 10.8537.3 ± 12.5137.5 ± 10.8337.1 ± 11.05
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mgTotal
Female43373939158
Male915131451
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mgTotal
White/Caucasian40363536147
Black/African American1013121651
Asian12216
American Indian/Alaska Native00101
Captured as Other11204
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mgTotal
Hispanic or Latino1057628
Not Hispanic or Latino41474447179
Unknown10001
Captured as Other00101
Mean abscess and inflammatory nodule (AN) count
Mean abscess and inflammatory nodule (AN) count(abscesses and inflammatory nodules)PlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mgTotal
Mean11.2 ± 5.8511.8 ± 7.1012.9 ± 12.3410.6 ± 7.2411.6 ± 8.48
Mean International Hidradenitis Suppurativa Severity Score System (IHS4) score
Mean International Hidradenitis Suppurativa Severity Score System (IHS4) score(scores on a scale)PlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mgTotal
Mean22.9 ± 17.0222.4 ± 23.2423.5 ± 22.7918.9 ± 17.2521.9 ± 20.21
Mean abscess, inflammatory nodule (IN), and draining fistula (DF) (ANF) count
Mean abscess, inflammatory nodule (IN), and draining fistula (DF) (ANF) count(abscesses, INs, and DFs)PlaceboINCB054707 15 mgINCB054707 45 mgINCB054707 75 mgTotal
Mean13.6 ± 6.3614.1 ± 10.0815.1 ± 13.5112.2 ± 8.9413.7 ± 10.03
08

Study locations

40 sites
  • Investigative Site 005
    Hoover, Alabama 35244, United States
  • Investigative Site 003
    Gilbert, Arizona 85295, United States
  • Investigative Site 011
    Phoenix, Arizona 85006, United States
  • Investigative Site 014
    Fountain Valley, California 92708, United States
  • Investigative Site 010
    Fremont, California 94538, United States
  • Investigative Site 012
    Huntington Beach, California 92647, United States
  • Investigative Site 022
    Newbury Park, California 91320, United States
  • Investigative Site 009
    Sacramento, California 95815, United States
  • Investigative Site 025
    Cromwell, Connecticut 06416, United States
  • Investigative Site 015
    Coral Gables, Florida 33134, United States
  • Investigative Site 021
    Miami, Florida 33136, United States
  • Investigative Site 006
    Tampa, Florida 33614, United States
  • Investigative Site 001
    Tampa, Florida 33624, United States
  • Investigative Site 016
    Atlanta, Georgia 30328, United States
  • Investigative Site 002
    West Lafayette, Indiana 47906, United States
  • Investigative Site 027
    Baton Rouge, Louisiana 70808, United States
  • Investigative Site 023
    New Orleans, Louisiana 70112, United States
  • Investigative Site 013
    Boston, Massachusetts 02215, United States
  • Investigative Site 004
    Fort Gratiot, Michigan 48059, United States
  • Investigative Site 019
    St Louis, Missouri 63110, United States
  • Investigative Site 026
    The Bronx, New York 10468, United States
  • Investigative Site 008
    Chapel Hill, North Carolina 27516, United States
  • Investigative Site 017
    Winston-Salem, North Carolina 27157, United States
  • Investigative Site 007
    Hershey, Pennsylvania 17033, United States
  • Investigative Site 018
    Bellaire, Texas 77401, United States
  • Investigative Site 101
    Calgary, Alberta T1Y 0B4, Canada
  • Investigative Site 102
    Calgary, Alberta T3A 0B2, Canada
  • Investigative Site 304
    Nantes, 44093, France
  • Investigative Site 403
    Berlin, 10117, Germany
  • Investigative Site 401
    Bochum, 44791, Germany
  • Investigative Site 405
    Dessau, 06847, Germany
  • Investigative Site 406
    Dresden, 01307, Germany
  • Investigative Site 404
    Erlangen, 91054, Germany
  • Investigative Site 402
    Frankfurt am Main, 60590, Germany
  • Investigative Site 552
    Rzeszów, 35-055, Poland
  • Investigative Site 551
    Wroclaw, 50-566, Poland
  • Investigative Site 553
    Wroclaw, 51-318, Poland
  • Investigative Site 703
    Granada, 18014, Spain
  • Investigative Site 702
    Madrid, 28007, Spain
  • Investigative Site 701
    Valencia, 46940, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Dec 2021, 15 months.

Results were first posted in Jan 2023, 1 year 1 month after primary completion.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 15 months is close to that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2020
First posted
Jul 17, 2020
StartActual
Aug 25, 2020
Primary completionActual
Dec 15, 2021
CompletionActual
Aug 16, 2023
Results first posted
Jan 26, 2023
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04476043
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jul 17, 2020
Start date
Aug 25, 2020
Primary completion
Dec 15, 2021
Completion
Aug 16, 2023
Results posted
Jan 26, 2023
Last update
Aug 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion